Table 1.
Clinical characteristics of HT patients (ALL) and HT patients divided in two disease-severity groups (MILD and OVERT).
| Phenotype | ALL | MILD | OVERT | P* |
|---|---|---|---|---|
| (N = 459) | (N = 240) | (N = 219) | ||
| Median (Q1–Q3) | Median (Q1–Q3) | Median (Q1–Q3) | ||
| Female, N (%) | 424 (92.37) | 226 (94.17) | 198 (90.41) | 0.129 |
| Age, years | 38.02 (27.76–48.49) | 35.81 (25.78–46.95) | 40.28 (31.04–50.37) | 0.002 |
| BMI, kg/m2 | 23.52 (20.76–26.85) | 23.15 (20.72–26.59) | 24.01 (21.02–26.99) | 0.043 |
| Vitamin D, ng/mL | 19.70 (14.40–25.20) | 20.70 (14.90–25.80) | 19.00 (13.95–24.55) | 0.055 |
| Vitamin D deficiency, N (%) | 238 (51.84) | 115 (47.92) | 123 (56.16) | 0.077 |
| Vitamin D insufficiency, N (%) | 172 (37.53) | 97 (40.42) | 75 (34.25) | 0.172 |
| Vitamin D sufficiency, N (%) | 49 (10.63) | 28 (11.66) | 21 (9.59) | 0.471 |
| TSH, mIU/L | 3.33 (1.74–5.68) | 3.23 (1.82–4.74) | 3.52 (1.67–12.30) | 0.010 |
| T3, nmol/L | 1.60 (1.30–1.80) | 1.70 (1.50–1.90) | 1.50 (1.20–1.80) | 0.002 |
| T4, nmol/L | 105 (89–118) | 106 (91–117.25) | 103 (84.85–121) | 0.203 |
| fT4, pmol/L | 12.10 (10.20–13.20) | 12.10 (10.90–13.10) | 11.90 (9.90–13.70) | 0.104 |
| TgAb, IU/mL | 135 (36.40–422.40) | 121.50 (26.40–321.30) | 192 (49.30–596.05) | < 0.001 |
| TPOAb, IU/mL | 212 (27.60–652.90) | 161.50 (17.40–529.75) | 273 (66.40–945.50) | < 0.001 |
| Thyroid volume, cm3 | 9.85 (7.30–13.91) | 9.89 (7.72–13.26) | 9.59 (6.82–14.90) | 0.414 |
| Number of symptoms, N | 4 (1–7) | 3 (1–6) | 5 (2–8) | < 0.001 |
| Systolic blood pressure, mmHg | 120 (110–130) | 115 (110–130) | 120 (110–130) | 0.279 |
| Diastolic blood pressure, mmHg | 70 (65–80) | 70 (65–78.75) | 70 (65–80) | 0.396 |
ALL, all HT patients; MILD, HT patients that were euthyroid or in subclinical hypothyroidism; OVERT, HT patients that were in overt hypothyroidism or treated with levothyroxine (LT4) therapy. *Mann–Whitney test/chi-square test between MILD and OVERT; Q1-first quartile, Q3-third quartile.